Patents by Inventor Xuexiang ZHANG

Xuexiang ZHANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR PREVENTING TOXICITY OF PLATINUM DRUGS
    Publication number: 20220202823
    Abstract: Methods for reducing platinum drug-induced toxicity in a cell expressing Organic Cation Transporter 2 (OCT2), methods for reducing platinum drug-induced toxicity in a subject, methods for treating cancer, methods for increasing efficacy of platinum drug treatment in a subject, and pharmaceutical compositions are described. The described methods and compositions include an OCT2 inhibitor where the OCT2 inhibitor is buflomedil or a salt thereof, dolutegravir or a salt thereof, contains an imidazole, or is miconazole or a salt thereof.
    Type: Application
    Filed: December 6, 2021
    Publication date: June 30, 2022
    Inventors: Yong HUANG, Dominique P. BRIDON, Xuexiang ZHANG, Chien-Ming LI
  • Methods of preventing toxicity of platinum drugs
    Patent number: 11197862
    Abstract: Methods for reducing platinum drug-induced toxicity in a cell expressing Organic Cation Transporter 2 (OCT2), methods for reducing platinum drug-induced toxicity in a subject, methods for treating cancer, methods for increasing efficacy of platinum drug treatment in a subject, and pharmaceutical compositions are described. The described methods and compositions include an OCT2 inhibitor where the OCT2 inhibitor is buflomedil or a salt thereof, dolutegravir or a salt thereof contains an imidazole, or is miconazole or a salt thereof.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: December 14, 2021
    Assignee: XOMICS BIOPHARMA, INC.
    Inventors: Yong Huang, Dominique P. Bridon, Xuexiang Zhang, Chien-Ming Li
  • METHODS OF PREVENTING TOXICITY OF PLATINUM DRUGS
    Publication number: 20180207169
    Abstract: Methods for reducing platinum drug-induced toxicity in a cell expressing Organic Cation Transporter 2 (OCT2), methods for reducing platinum drug-induced toxicity in a subject, methods for treating cancer, methods for increasing efficacy of platinum drug treatment in a subject, and pharmaceutical compositions are described. The described methods and compositions include an OCT2 inhibitor where the OCT2 inhibitor is buflomedil or a salt thereof, dolutegravir or a salt thereof contains an imidazole, or is miconazole or a salt thereof.
    Type: Application
    Filed: July 15, 2016
    Publication date: July 26, 2018
    Inventors: Yong HUANG, Dominique P. BRIDON, Xuexiang ZHANG, Chien-Ming LI